AusperBio Therapeutics has completed patient enrollment in two Phase II clinical trials of its lead drug candidate AHB-137 for chronic hepatitis B (CHB).
Trial Designs
- AB-10-8007 (NCT07069569): Randomized, open-label, multicenter.
- Evaluates AHB-137 + HBV vaccine or Peg-IFN in HBeAg-negative patients on nucleos(t)ide analogue (NA) therapy. - AB-10-8008 (NCT06829329): Randomized, multicenter.
- Tests AHB-137 in treatment-naïve CHB patients.
Why Combination Matters
“Combination therapies have been key to curing chronic viral infections like HIV and HCV,”
- Dr. Guofeng Cheng, CEO, AusperBio.
- AB-10-8007: Seeks to boost functional cure rates by pairing AHB-137 with existing HBV treatments.
- AB-10-8008: Expands AHB-137 to a broader HBV patient population.
- Interim results expected at global conferences in 2026.
Looking Ahead
“Enrollment completion moves us closer to Phase III.”
- Dr. Chris Yang, CSO, AusperBio.
- Phase III trial recently approved in China.
- Company aims to deliver a functional cure for HBV patients globally.
About AHB-137
- Novel antisense oligonucleotide (ASO).
- Built using Med-Oligo ASO technology platform.
- Designed to deliver a dual mechanism of action.
- Strong data from EASL, AASLD, and APASL presentations.
- Progressing through multiple Phase II studies and one Phase III trial in China.
AusperBio’s Focus
AusperBio is a clinical-stage biotech with operations in the USA and China.
- Dedicated to oligonucleotide and targeted delivery technologies.
- Lead focus: Achieving a functional cure for chronic hepatitis B.
